标题
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
作者
关键词
-
出版物
Biomarker Research
Volume 8, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-26
DOI
10.1186/s40364-020-00209-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
- (2020) N. Chaput et al. ANNALS OF ONCOLOGY
- CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
- (2020) Enriqueta Felip et al. EUROPEAN JOURNAL OF CANCER
- Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC
- (2020) Kai Zhang et al. CLINICAL CANCER RESEARCH
- Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).
- (2020) Yutaro Tamiya et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.
- (2020) Charles S. Fuchs et al. JOURNAL OF CLINICAL ONCOLOGY
- The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.
- (2020) Kohei Shitara et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
- (2020) Weimin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- TAS-116, an oral HSP90 inhibitor, in combination with nivolumab in patients with colorectal cancer and other solid tumors: An open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
- (2020) Akihito Kawazoe et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
- (2020) Weimin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
- (2020) Kobe C. Yuen et al. NATURE MEDICINE
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
- (2019) Bo Gong et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Surprisingly Positive Association Between Obesity and Cancer Immunotherapy Efficacy
- (2019) William J. Murphy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer
- (2019) Wenfeng Fang et al. CLINICAL CANCER RESEARCH
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
- (2019) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
- (2019) Sonja Althammer et al. Journal for ImmunoTherapy of Cancer
- Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer
- (2019) Dickran Kazandjian et al. JAMA Oncology
- Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
- (2019) Liangliang Cai et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
- (2019) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Tumor neoantigens: from basic research to clinical applications
- (2019) Tao Jiang et al. Journal of Hematology & Oncology
- Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types
- (2019) Feng Wang et al. JAMA Oncology
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
- (2019) Jiefei Han et al. Cancer Immunology Research
- Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors
- (2019) Zhijie Wang et al. Journal of Thoracic Oncology
- Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer
- (2019) Brian C. Baumann et al. JAMA Oncology
- Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information
- (2018) S Kim et al. ANNALS OF ONCOLOGY
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
- (2018) Marzia Del Re et al. BRITISH JOURNAL OF CANCER
- Genomic Features of Response to Combination Immunotherapy in Lung Cancer
- (2018) Martin Früh et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
- (2018) Sachet A. Shukla et al. CELL
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
- (2018) Curtis H. Kugel et al. CLINICAL CANCER RESEARCH
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
- (2018) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- (2018) Alexandra K. Rzepecki et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhancing responses to cancer immunotherapy
- (2018) Pia Kvistborg et al. SCIENCE
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
- (2018) Andrew J. Rech et al. Cancer Immunology Research
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
- (2018) Jenny H. Lee et al. JAMA Oncology
- Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
- (2018) Priyanka B. Subrahmanyam et al. Journal for ImmunoTherapy of Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
- (2018) Suresh S. Ramalingam et al. CANCER RESEARCH
- Association of tumor mutational burden with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer
- (2018) Young Kwang Chae et al. Clinical Lung Cancer
- Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
- (2018) Fatema A. Legrand et al. JOURNAL OF CLINICAL ONCOLOGY
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
- (2018) Christof C. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
- (2018) Jeffrey J. Ishizuka et al. NATURE
- Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
- (2018) Ziming Wang et al. NATURE MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab
- (2017) Julia K. Tietze et al. EUROPEAN JOURNAL OF CANCER
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
- (2017) Marcin Kowanetz et al. Journal of Thoracic Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
- (2017) Elizabeth Dudnik et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- How T cells spot tumour cells
- (2017) NATURE
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
- (2017) Marta Łuksza et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
- (2017) Yingyi Zhang et al. Oncotarget
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
- (2017) Hye In Kim et al. OncoImmunology
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
- (2016) Tomohiro F. Nishijima et al. CANCER TREATMENT REVIEWS
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
- (2016) J. Galon et al. Journal of Translational Medicine
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
- (2016) Hiroyuki Inoue et al. OncoImmunology
- Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non–Small-Cell Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- T cell exclusion, immune privilege, and the tumor microenvironment
- (2015) J. A. Joyce et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Circulating Tumor DNA as a Liquid Biopsy for Cancer
- (2014) E. Heitzer et al. CLINICAL CHEMISTRY
- Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
- (2014) Fei Duan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- The immune landscape of human tumors
- (2014) Gabriela Bindea et al. OncoImmunology
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights
- (2013) X. Wang et al. CLINICAL CANCER RESEARCH
- A signature of immune function genes associated with recurrence-free survival in breast cancer patients
- (2011) Maria Libera Ascierto et al. BREAST CANCER RESEARCH AND TREATMENT
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction
- (2011) Bernhard Mlecnik et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
- (2008) Agop Y. Bedikian et al. CANCER INVESTIGATION
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now